

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method of identifying agents that regulate the transcriptional activating activity of human androgen receptor, or estrogen receptor β , comprising:
 - contacting a cell expressing human androgen receptor or human estrogen receptor β , and, human skeletal muscle LIM-protein 3, or a biologically-active derivative thereof, with a test agent; and
 - determining whether said test agent regulates the transcriptional activating activity of human androgen receptor or estrogen receptor β ,
wherein said biologically-active derivative is at least 90% homologous to human skeletal muscle LIM-protein3 and functions as a co-activator for androgen receptor and estrogen receptor β .
2. (Original) A method of claim 1, wherein said cell is a 293 cell or a yeast cell.
3. (Previously presented) The method of claim 1, wherein said determining is measuring transcription of a gene activated by human androgen receptor or human estrogen receptor β .
4. (Previously presented) The method of claim 1, wherein said human androgen receptor or human estrogen receptor β is a chimeric protein comprising a GAL4 binding domain and skeletal muscle LIM-protein 3 is a chimeric protein comprising a GAL4 activator domain.
5. (Original) A method of claim 4, wherein said cell is a yeast cell comprising a β -galactosidase reporter gene.
6. (Original) A method of claim 5, where said yeast cell is *Saccharomyces cerevisiae*

7. (Original) A method of claim 4, wherein said determining is measuring β-galactosidase activity.

8. (Cancelled)

9. (Original) A method of claim 1, where said agent is an antagonist or an agonist.

10. (Withdrawn) A method of identifying agents that regulate the binding between SLIM3 and human AR or ERβ, comprising:

contacting a sample comprising human SLIM3 and human AR or human ERβ, or biologically-active derivatives thereof, with a test agent; and

determining whether said test agent regulates the binding between said SLIM3 and said human AR or human ERβ.

11. (Withdrawn) A method of claim 9, where said SLIM3 is a chimeric protein comprising GST.

12. (Withdrawn) A composition comprising isolated human SLIM3 and isolated human AR or ERβ.

13. (Currently Amended) A method of identifying agents that regulate an agent that regulates the transcriptional activating activity of human androgen receptor or estrogen receptor β, comprising:

contacting a cell expressing human androgen receptor or human estrogen receptor β, and human skeletal muscle LIM-protein3, or an allelic modification derivative thereof, with a test agent; and

determining whether said test agent regulates the transcriptional activating activity of human androgen receptor or human estrogen receptor β,

Appl. Serial No.: 09/909,762
Attorney Docket No.: SCH-1700D1
Reply Dated November 18, 2003
Reply to Office Action of July 28, 2003
and November 12, 2003

wherein said allelic derivative is at least 90% homologous to human skeletal muscle LIM-protein3 and maintains at least 80% of the activity of human skeletal muscle LIM-protein3 as a co-activator for androgen receptor and estrogen receptor β.

14. (Currently Amended) A method of identifying agents that regulate an agent that regulates the transcriptional activating activity of human androgen receptor or estrogen receptor β, comprising:

contacting a cell expressing human androgen receptor or human estrogen receptor β, and human skeletal muscle LIM-protein3, with a test agent; and

determining whether said test agent regulates the transcriptional activating activity of human androgen receptor or human estrogen receptor β.